Search clinical trials for: Tisotumab Vedotin

Total 396 results

Sun Yat-sen University

Not yet recruiting

A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Pancreatic Cancer
University of Alabama at Birmingham
Seagen Inc.; Kyowa Kirin, Inc.

Recruiting

Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

Mycosis Fungoides | Cutaneous T Cell Lymphoma

United States
M.D. Anderson Cancer Center
Seagen Inc.

Recruiting

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

Mycosis Fungoides

United States
Hoffmann-La Roche

Active, not recruiting

Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma

United States, Israel, Spain, Korea, Republic of, Poland, Taiwan
Seagen Inc.

Completed

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Acute Myeloid Leukemia | Solid Tumors | Acute Lymphoid Leukemia | Anemia, Refractory, With Excess of Blasts

United States
Takeda

Completed

Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)

Hodgkin Disease | Lymphoma, Large-Cell, Anaplastic

China
Massachusetts General Hospital
Seagen Inc.

Terminated

Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)

GVHD | Graft-vs-Host Disease

United States
Grupo Español de Linfomas y Transplante Autólogo...

Recruiting

BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant (BRESELIBET)

Hodgkin Lymphoma, Adult

Spain
University of Colorado, Denver
National Cancer Institute (NCI)

Withdrawn

POLA+BR for Relapsed or Refractory DLBCL

Diffuse Large B Cell Lymphoma
Tianjin Medical University Second Hospital

Recruiting

Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC)

Neoadjuvant Immunotherapy

China
Qilu Hospital of Shandong University

Not yet recruiting

First-line Treatment With RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer (RCTS)

HER2-positive Gastric Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

RC-48 Combined With GLS-010 in HER2-overexpressed Patients With Previously Treated Unresectable Biliary Tract Cancer (RIGHT)

Biliary Carcinoma

China
National Institute of Allergy and Infectious Diseases...
PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN); Seagen...

Completed

Brentuximab Vedotin for Systemic Sclerosis (BRAVOS)

Diffuse Cutaneous Systemic Sclerosis | Scleroderma | dcSSc

United States
Memorial Sloan Kettering Cancer Center
MethylGene Inc.

Completed

Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Hodgkin Lymphoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Seagen Inc.

Withdrawn

Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly

Lymphoma
Fudan University

Recruiting

Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC

HER2-positive Gastric Cancer | Immunotherapy

China
Seagen Inc.

Completed

A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin | Lymphoma, T-Cell

United States, Canada
University of Cologne

Recruiting

Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma

Classical Hodgkin Lymphoma

Germany
University of Birmingham
Millennium Pharmaceuticals, Inc.; Leukaemia Lymphoma Research

Completed

A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity (BREVITY)

Hodgkin Disease

United Kingdom
Takeda

Completed

Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Untreated CD30-Positive Hodgkin's Lymphoma"

Untreated CD30-Positive Hodgkin's Lymphoma

Japan
Takeda

Completed

Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"

Peripheral T Cell Lymphoma | Pediatric Hodgkin Lymphoma

Japan
Genentech, Inc.

Completed

A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (ROMULUS)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma

United States, Canada, France, Italy, Germany, Netherlands
Henan Cancer Hospital

Not yet recruiting

Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression

Gastric Cancer

China
Hoffmann-La Roche

Completed

A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

Non-Hodgkin's Lymphoma

United States, Australia, Italy
Sidney Kimmel Comprehensive Cancer Center at Johns...
Genentech, Inc.

Terminated

Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma

Lymphoma

United States
Astellas Pharma Inc
Seagen Inc.

Completed

A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (EV-201)

Urologic Neoplasms | Urinary Bladder Neoplasms | Carcinoma, Transitional Cell | Ureteral Neoplasms | Urothelial Cancer | Urethral Neoplasms | Renal Pelvis Neoplasms

United States, Korea, Republic of, Spain, France, Germany, Italy, Japan, Netherlands
Merck Sharp & Dohme LLC

Active, not recruiting

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

Urothelial Carcinoma

Australia, United States, Chile, Denmark, Israel, Korea, Republic of, Spain
Alshimaa Abbas Mohamed Ebrahim

Active, not recruiting

Effect of Oral Isotretinoin on The Level of SerumYKL40 in Acne Vulgaris Patients

Acne Vulgaris

Egypt
Seagen Inc.
Bristol-Myers Squibb

Completed

A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

Hodgkin Lymphoma

United States
Changhai Hospital

Not yet recruiting

DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With HER2 IHC2+/3+ ESCC

HER-2 Protein Overexpression | Esophageal Squamous Carcinoma
Fondazione Italiana Linfomi ONLUS

Completed

Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disease. (FIL_BVHD01)

Hodgkin Lymphoma

Italy
Lazaros Lekakis
Genentech, Inc.

Recruiting

CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).

Refractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | Aggressive Non-Hodgkin Lymphoma

United States
Seagen Inc.

Completed

Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma

Hodgkin Disease

United States
Yale University
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

T-Cell Lymphoma

United States
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

Urothelial Carcinoma | HER2-expressing

China
Lawson Health Research Institute
Seagen Inc.

Recruiting

Open Label Extension Study of Brentuximab Vedotin in Early dcSSc

Diffuse Cutaneous Systemic Sclerosis

Canada
Washington University School of Medicine
Celgene; Seagen Inc.

Completed

Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma

Lymphoma, Large B-Cell, Diffuse

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nanfang Hospital of Southern Medical University; The Third Affiliated Hospital... and other collaborators

Not yet recruiting

A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma

Bladder Cancer
Multinational Center for Quality of Life Research...

Unknown

Patient-reported and Clinical Outcomes in Adults With Relapsed or Refractory Hodgkin's Lymphoma Receiving Brentuximab Vedotin

Relapsed or Refractory Hodgkin's Lymphoma

Russian Federation
Shanghai Zhongshan Hospital

Not yet recruiting

Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer

Colorectal Neoplasms
Fondazione Italiana Linfomi ONLUS

Completed

Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients

Lymphatic Diseases

Italy
ADC Therapeutics S.A.

Recruiting

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

B-Cell Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed B-Cell Non-Hodgkin Lymphoma

United States, Spain, Italy, United Kingdom, Belgium, Czechia
RemeGen Co., Ltd.

Recruiting

DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

Breast Cancer

China
M.D. Anderson Cancer Center

Terminated

Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)

Lymphoma

United States
Eric Bernicker, MD
Millennium Pharmaceuticals, Inc.; The Methodist Hospital Research Institute

Withdrawn

Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies (AD3LE)

CD30-positive Lymphoma | CD30-positive Solid Tumor

United States
GE Healthcare

Completed

Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images

Mild Cognitive Impairment | Alzheimer's Disease
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

First-line Treatment | HER2-positive Metastatic Breast Cancer

China
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd; Seagen Inc.

Terminated

A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant, (CheckMate 812)

Hodgkin's Disease

United States, Japan, Puerto Rico
The Lymphoma Academic Research Organisation

Completed

Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine

Refractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell Lymphoma

France, Belgium
Federal Research Institute of Pediatric Hematology...

Recruiting

Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT) (BASALT)

Hodgkin's Lymphoma

Russian Federation

3

Subscribe